XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
1.250
-0.010 (-0.79%)
Nov 21, 2024, 11:32 AM EST - Market open

Company Description

XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection.

It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy.

It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.

XORTX Therapeutics Inc.
XORTX Therapeutics logo
Country Canada
Founded 2011
Industry Biotechnology
Sector Healthcare
Employees 3
CEO Allen Davidoff

Contact Details

Address:
3710 – 33rd Street NW
Alberta Beach, AB T2L 2M1
Canada
Phone 403 455 7727
Website xortx.com

Stock Details

Ticker Symbol XRTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001729214
CUSIP Number 98420Q207
ISIN Number CA98420Q3061
SIC Code 2834

Key Executives

Name Position
Dr. Allen Warren Davidoff Ph.D. Founder, Chief Executive Officer, President and Director
James Neville Fairbairn C.A., C.P.A., ICD.D Chief Financial Officer
Dr. Stephen Haworth M.D., MRCP Chief Medical Officer
Dr. Stacy Evans M.B.A., M.D. Chief Business Officer
Nick Rigopoulos Director of Communications
Dr. David Sans M.B.A., Ph.D. Director of Corporate Development
Dr. David MacDonald Ph.D. Consultant of Clinical Operations
Charlotte May Corporate Secretary

Latest SEC Filings

Date Type Title
Nov 15, 2024 F-1 Registration statement for certain foreign private issuers
Nov 15, 2024 6-K Report of foreign issuer
Oct 31, 2024 D Notice of Exempt Offering of Securities
Oct 24, 2024 6-K Report of foreign issuer
Oct 18, 2024 6-K Report of foreign issuer
Oct 18, 2024 6-K Report of foreign issuer
Oct 18, 2024 6-K Report of foreign issuer
Oct 18, 2024 424B5 Filing
Oct 17, 2024 6-K Report of foreign issuer
Oct 17, 2024 424B5 Filing